Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Avant Diagnostics, Inc. (OTC: AVDX).

Full DD Report for AVDX

You must become a subscriber to view this report.


Recent News from (OTC: AVDX)

Amarantus Re-acquires Rights to Alzheimer's Blood Diagnostic LymPro Test
NEW YORK, April 06, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire --  Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therap...
Source: GlobeNewswire
Date: April, 06 2018 11:23
Amarantus Appoints Barney Monte as Interim COO/CFO and Promotes Brian Harvey to Chief Regulatory Advisor
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic ther...
Source: GlobeNewswire
Date: April, 05 2018 08:00
Amarantus Relocates Headquarters to WeWork at 110 Wall St. in New York City
SAN FRANCISCO, April 02, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire --   Amarantus Bioscience Holdings, Inc. (OTCPink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalm...
Source: GlobeNewswire
Date: April, 02 2018 09:49
Amarantus Completes Tender Exchange of Convertible Securities; CEO attending CNBC's Healthy Returns conference in New York City
SAN FRANCISCO, March 28, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS ) (the "Company" or AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ...
Source: GlobeNewswire
Date: March, 28 2018 13:41
Avant Diagnostics' Newly Appointed President & CEO Philippe Goix Delivered an Address to Shareholders
GAITHERSBURG, Maryland , September 27, 2017 /PRNewswire/ -- Avant Diagnostics, Inc. ("Avant" or the "Company") (OTC: AVDX), an oncology-focused healthcare technology company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, tod...
Source: PR Newswire
Date: September, 27 2017 16:05
Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway Activation Data Predicting Tamoxifen® and Other Endocrine Treatment Response in Estrogen Receptor Positive (ER+) Breast Cancer
GAITHERSBURG, Maryland , July 18, 2017 /PRNewswire/ -- Two thirds of all breast cancer (BC) tumors are estrogen receptor positive (ER)+ ER+ BC patients have mixed responses to endocrine therapy Research demonstrates mTOR pathway activation status prospectively predicts endocrine t...
Source: PR Newswire
Date: July, 18 2017 07:30
Avant Diagnostics Acquires Exclusive Option to License Genetic Health Solution Technology Platform
GAITHERSBURG, Maryland , July 12, 2017 /PRNewswire/ -- Genetic Health Solution platform helps chronic disease patient management Patient-centric biomarker-based wellness programs designed to improve outcomes Avant Diagnostics, Inc. ("Avant") (OTC: AVDX), an oncology-focused He...
Source: PR Newswire
Date: July, 12 2017 14:10
Avant Diagnostics Announces Confirmatory Clinical Utility Data for Theralink® in Pancreatic Cancer
GAITHERSBURG, Maryland , June 27, 2017 /PRNewswire/ -- - Theralink predicts 5-year survival for patients in response to standard of care - Negative predictive value allows physicians to change treatment decisions Avant Diagnostics, Inc. ('Avant') (OTC: AVDX), an oncology-focu...
Source: PR Newswire
Date: June, 27 2017 07:30
Avant Diagnostics Appoints Philippe Goix, PhD, MBA as President & CEO to Commercialize Proprietary Theralink® Tumor Biomarker Platform
GAITHERSBURG, Maryland , June 21, 2017 /PRNewswire/ -- Dr. Goix brings 20 years of successful healthcare commercialization experience Two posters were presented at ASCO June 3 rd , 2017 for Theralink® Breast Cancer Avant Diagnostics, Inc. ("Avant") (OTC: AVDX), an ...
Source: PR Newswire
Date: June, 21 2017 09:27
Avant Diagnostics Presented Data on TheraLink® Pancreatic Cancer Assay at the International Symposium on Pancreas Cancer 2016
SCOTTSDALE, Ariz. and GAITHERSBERG, Md., June 14, 2016 (GLOBE NEWSWIRE) -- Avant Diagnostics, Inc. (“Avant”) (OTCQB:AVDX), an innovative molecular diagnostics company, today announced that Dr. Vince Picozzi presented data on use of the Company’s TheraLink® assay ...
Source: GlobeNewswire
Date: June, 14 2016 09:02

 


About Avant Diagnostics, Inc. (OTC: AVDX)

Logo for Avant Diagnostics, Inc. (OTC: AVDX)

Avant Diagnostics, Inc. Avant , we or the Company , a Nevada corporation established in , is a diagnostic company that focuses on the commercialization of a series of proprietary microarray based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe disease states. . The Company s premier product is OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The Company believes this test could be approved by the U.S. Food and Drug Administration FDA as the first pre symptomatic screening test for ovarian cancer in the United States, detecting all types and all stages of ovarian cancer with high sensitivity and specificity.

 

 

 

Current Management

  • Gregg Linn / CEO, CFO, COO
  • Michael Linn / Controller
  • Gregg Linn / Chairman
  • Randall Letcavage /
  • Joseph Roth /

Current Share Structure

  • Market Cap: $5,400,835 - 03/16/2018
  • Authorized: 450,000,000 - 03/01/2018
  • Issue and Outstanding: 306,865,649 - 03/01/2018
  • Float: 2,225,465 - 03/31/2016

 


Recent Filings from (OTC: AVDX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 18 2017
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: November, 28 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 22 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 28 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 26 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: September, 26 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 31 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 24 2017

 

 


Daily Technical Chart for (OTC: AVDX)

Daily Technical Chart for (OTC: AVDX)


Stay tuned for daily updates and more on (OTC: AVDX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AVDX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVDX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of AVDX and does not buy, sell, or trade any shares of AVDX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/